This is a working overview of WADA Prohibited List, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-24 and is reviewed periodically as new material appears.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Mitch McConnell, who led Trump's Republican Party in the Senate from 2007 to 2025, characterised attempts to seize Greenland as "trampling the sovereignty, respect, and trust of our allies" and that "the use of force ... would be an especially catastrophic act of strategic self-harm to America and its global influence". Republican senator Susan Collins and Speaker of the House of Representatives Mike Johnson called the threats and possible US military actions as "completely inappropriate". In mid-January, a delegation of US congresspeople from both major political parties, including senators Chris Coons, Lisa Murkowski, Jeanne Shaheen, and Thom Tillis, travelled to Copenhagen to meet with Danish and Greenlandic officials to underscore the value of their partnership. Former assistant secretary of state for arms control, verification, and compliance Frank A. Rose, the last US official to negotiate a defence agreement with Denmark, said Trump's behaviour threatened to undermine the access the United States had to the Danish territory, since, under the 1951 agreement, the US already had all the military access it needed.
Fragrances are detected by the nose when the movement of inspired air contacts olfactory sensory neurons, which in humans, number between 6 and 10 million over a surface area of 2.5 cm2 (0.39 sq in) of olfactory epithelium. Fragrance signals are conveyed from the epithelium to the olfactory nerves, and then to the olfactory bulbs, which relay neural impulses about fragrance properties into the primary olfactory cortex of the brain. In the olfactory cortex, fragrance characteristics are integrated to evaluate the safety and appeal of compounds to be ingested, and to recognize environmental and social factors associated by memory with the fragrance.
=== Canonical consensus motif === CK1δ preferably interacts with phospho-primed or acidic substrates due to the localization of positively charged amino acids (e.g. Arg-178 and Lys-224) in the region involved in substrate recognition. The canonical consensus motif targeted by CK1 is represented by the sequence pSer/pThr-X-X-(X)-Ser/Thr. In this motif X stands for any amino acid while pSer/pThr indicates a previously phosphorylated serine or threonine residue. CK1-mediated phosphorylation occurs at the Ser/Thr downstream of the phospho-primed residue. However, instead of a primed residue also a cluster of negatively charged amino acid residues (Asp or Glu) can be included in the canonical consensus motif.
Naram-Sin defeated Manium of Magan, and various northern hill tribes in the Zagros, Taurus, and Amanus Mountains, expanding his empire up to the Mediterranean Sea. His "Victory Stele" depicts his triumph over Satuni, chief of Lullubi in the Zagros Mountains. The Sumerian King List gives the length of his reign as 56 years, and at least 20 of his year-names are known, referring to military actions against various places such as Uruk and Subartu. One unknown year was recorded as "the Year when Naram-Sin was victorious against Simurrum in Kirasheniwe and took prisoner Baba the governor of Simurrum, and Dubul the ensi of Arame". Other year names refer to his construction work on temples in Akkad, Nippur, and Zabala. He also built administrative centers at Nagar and Nineveh. In general it is not possible to assign an order to Naram-Sin's year name with the exception of his first "The year Naram-Sin received a weapon of heaven/An fr[om] the temple of the god Enlil". It is, however, possible to divide them into those before his deification and after that event (assumed to be shortly after the "Great Revolt") based on the presence of a godhood determinant in his name. During his reign Naram-Sin increased direct royal control of its city-states. He maintained control over the various city-states by the simple expedient of appointing some of his many sons as key provincial governors, and his daughters as high priestesses. He also reformed the scribal system. A few loyal local governors remained in place.
=== Dextran-crosslinked microspheres === One application of the glucose polymer dextran in microsphere compositions is as a cross-linker. Dextran and oxidized dextran can be used to crosslink gelatin microspheres to reduce gelatin dissolution, which slows the drug release rate. These dextran/gelatin microspheres can be used to provide slow-release of TRAPP-Br, which is a cancer therapeutic. Hydrogel microspheres synthesized by using porous chitosan polyelectrolyte complex with dextran sulfate as a cross-linker can deliver hydrophobic drugs to the intestines with high efficacy.
Sources: en.wikipedia.org
=== Probing pocket depth (PPD) === Pocket depth is the distance from the gingival margin to the base of the pocket. The position of the gingival margin can change due to swelling or recession, and vary with inflammation if force of probing, therefore, probing depth measurement alone is not recommended for assessment of changes in periodontal support over time.
==== N-Acetylcysteine ==== A systematic review and meta-analysis of 5 studies found that N-acetylcysteine reduces depressive symptoms more than placebo and has good tolerability. N-acetylecysteine may exert its benefits by replenishing the chief cellular antioxidant, glutathione, thus modulating glutamatergic, neurotropic and inflammatory pathways.
Loss of liquid level in the vessel may lead to gas blowby where high pressure gas flows to the downstream vessel through the liquid outlet line. The structural integrity of the downstream vessel can be compromised. In addition high liquid level in the vessel may lead to carryover of liquid into the gas outlet may damage downstream equipment such as gas compressors. High liquid level in a flare drum can lead to undesirable carryover of liquid to the flare. A high-high liquid level (LSHH) in the flare drum initiates a plant shutdown. One of the problems with a significant number of technologies is that they are installed through a nozzle and are exposed to products. This can create several problems, especially when retrofitting new equipment to vessels that have already been stress relieved, as it may not be possible to fit the instrument at the location required. Also, as the measuring element is exposed to the contents within the vessel, it may either attack or coat the instrument causing it to fail in service. One of the most reliable methods for measuring level is using a nuclear gauge, as it is installed outside the vessel and doesn't normally require a nozzle for bulk level measurement. The measuring element is installed outside the process and can be maintained in normal operation without taking a shutdown. Shutdown is only required for an accurate calibration.
They achieve this by importing the lymphocytes from blood and lymph. According to the composition and activation status of the cells within the lymphoid structures, at least three organizational levels of TLOs have been described. The formation of TLOs starts with the aggregating of lymphoid cells and occasional DCs, but FDCs are lacking at this stage. The next stage is immature TLOs, also known as primary follicle-like TLS, which have an increased number of T cells and B cells with distinct T cell and B cell zones and the formation of FDCs network, but without germinal centres. Finally, fully mature (also known as secondary follicle-like) TLOs often have active germinal centres and high endothelial venules (HEVs), demonstrating a functional capacity by promoting T cell and B cell activation and then leading to expansion of TLS through cell proliferation and recruitment. During TLS formation, T and B cells are separated into two distinct but adjacent zones, with some cells able to migrate from one to the other, which is a crucial step in developing an effective and coordinated immune response. TLOs may play a key role in the immune response to cancer and serve as a prognostic marker for immunotherapy. TLOs have been reported to present in different cancer types such as melanoma, non-small-cell lung cancer and colorectal cancer (reviewed by Sautès-Fridman and colleagues in 2019), as well as glioma. TLOs are also seen as a read-out of treatment efficacy.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.